Zeidner, Joshua F <br/><br/>
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).  [electronic resource] 

 -  Leukemia research  09 2018 
 - 92-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Letter; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2018.08.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Female<br/>Flavonoids--administration & dosage<br/>Humans<br/>Leukemia, Myeloid, Acute--diagnosis<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Piperidines--administration & dosage<br/>Risk Factors